➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Baxter
Dow
Boehringer Ingelheim

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,460,641


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,460,641
Title:Microemulsion process and composition
Abstract: An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.
Inventor(s): Larm; Maria Graziella (Rosanna, AU), Harding; Ronald (North Warrandyte, AU), Johnston; Michael (Yarraville, AU), Abram; Albert Zorko (Wantirna, AU), Vijayakumar; Prema (Fremont, CA), Sun; Phoebe (Mountain View, CA)
Assignee: Stiefel Research Australia Pty Ltd (Rowville, AU)
Application Number:11/216,668
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

Drugs Protected by US Patent 8,460,641

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan OLUX E clobetasol propionate AEROSOL, FOAM;TOPICAL 022013-001 Jan 12, 2007 AB2 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES ⤷  Free Forever Trial
Almirall VERDESO desonide AEROSOL, FOAM;TOPICAL 021978-001 Sep 19, 2006 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF ATOPIC DERMATITIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,460,641

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 051197 ⤷  Free Forever Trial
Australia 2005279704 ⤷  Free Forever Trial
Brazil PI0514806 ⤷  Free Forever Trial
Canada 2578594 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.